HLBack of Napkin
Herbalife Nutrition Ltd. HLF
Written 2026-07-07. The company has filed a quarterly or annual report since, on 2026-08-05, so figures here predate its latest disclosure.
Herbalife trades at 5.7x earnings and 3.6x free cash flow with a $1.37B market cap on $5.0B of revenue, a business the market has priced for terminal decline while it quietly delevers.
The asymmetry is a shrinking-but-cash-gushing MLM paying down debt fast enough that equity value compounds even at zero revenue growth; a deleveraging trade, not a growth story.
Key data
HLF · price with moving averages
Source: market data.
The business
Herbalife sells weight-management shakes, protein powders, teas, and supplements through a multi-level distributor network across roughly 90 countries. Revenue is diversified geographically, with North America, Latin America (Mexico is the single largest country), EMEA, and Asia Pacific each contributing meaningful slices; no single region carries the franchise. The engine that matters is the distributor base: independent distributors and preferred customers who both consume the product and recruit the next layer. Distributor productivity, not shelf placement or advertising, drives the top line. FY25 revenue of $5.04B was up 0.9% versus FY24's $4.99B, a stabilization after years of gradual decline from the 2021 peak near $5.8B.
The qualitative fact the financials do not show: this is a business the FTC extracted a $200M settlement from in 2016 over deceptive earnings claims, that Bill Ackman spent five years and hundreds of millions shorting as a pyramid scheme, and that still carries structural questions about distributor economics. What has changed is the demographic mix and the channel: nutrition clubs (physical locations run by distributors) now anchor a meaningful share of volume in Latin America and among Hispanic communities in the US, giving the model a community-anchored retail feel that the older door-to-door MLM shape lacked. GLP-1 weight-loss drugs are the visible overhang; management's counter is that shakes complement rather than compete with pharmacotherapy. That thesis is unproven.
Inside the complete Back of Napkin
- 01The business
- 02The numbers
- 03Management
- 04The linchpins
- 05Closing
- 06Methodology
Continue with HLF
Get the complete Back of Napkin free.
Choose this as your free complete report. No card required.
Read the complete reportAlready a member? Sign in

